Intelligent Ultrasound Group PLC Investor presentation

TIDMIUG

Intelligent Ultrasound Group PLC

28 April 2022

Intelligent Ultrasound Group plc

("Intelligent Ultrasound" or the "Group")

Investor Presentation

Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound artificial intelligence (AI) software and simulation group, is pleased to announce that Stuart Gall, CEO, and Helen Jones, CFO, will provide a live presentation relating to Preliminary Results via the Investor Meet Company platform on Tuesday, 3rd May 2022 at 2:15pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Intelligent Ultrasound Group plc via: https://www.investormeetcompany.com/intelligent-ultrasound-group-plc/register-investor

Investors who already follow Intelligent Ultrasound Group plc on the Investor Meet Company platform will automatically be invited.

For further information, please contact:

 
Intelligent Ultrasound Group plc                                                www. intelligentultrasound.com 
Stuart Gall, CEO                                                                      Tel: [phone] 
 
Helen Jones, CFO 
 
 
Cenkos Securities - Nominated Advisor                                                 Tel: [phone] 
 and Broker 
Giles Balleny / Max Gould (Corporate 
 Finance) 
Michael Johnson / Julian Morse 
 (Sales) 
 
 
 
Walbrook PR                                   Tel: [phone] or [e-mail] 
Anna Dunphy / Paul McManus                                         Mob: [phone] / Mob: [phone] 
                                                                                                       541 893 
 
 
 

About Intelligent Ultrasound Group

Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:

Simulation

Focusses on real-time hi-fidelity ultrasound education and training through simulation. Its main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,350 simulators have been sold to over 650 medical institutions around the world.

Clinical AI software

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson SWIFT ultrasound machine; ScanNav Anatomy PNB that simplifies ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting for a range of medical procedures; and NeedleTrainer that teaches real-time ultrasound guided needling and incorporates ScanNav Anatomy PNB.

www.intelligentultrasound.com

NOTE: ScanNav Anatomy PNB is not yet available for sale in the US or any other territory requiring government approval for this type of product.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABKOBKABKDNQB

(END) Dow Jones Newswires

April 28, 2022 02:02 ET (06:02 GMT)